Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9R0G

Human CD73 (ecto 5'-nucleotidase) in complex with compound 21

これはPDB形式変換不可エントリーです。
9R0G の概要
エントリーDOI10.2210/pdb9r0g/pdb
分子名称5'-nucleotidase, ZINC ION, CALCIUM ION, ... (7 entities in total)
機能のキーワード5'-nucleotidase, hydrolase, phosphatase, inhibitor
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計120952.86
構造登録者
Moore, J.T.,Ivic, N.,Lammens, A.,Krapp, S.,Maskos, K. (登録日: 2025-04-24, 公開日: 2025-11-12, 最終更新日: 2025-11-26)
主引用文献Moore, J.T.,Kawai, H.,Blank, B.R.,Wu, K.,Yeh, C.H.,Zhu, L.,Pham, J.D.,Rew, Y.,Eksterowicz, J.,Salaniwal, S.,Sutimantanapi, D.,Warne, R.,Yuen, N.,Metzger, T.C.,Chan, B.,Huang, T.,Chen, X.,Chen, Y.,Duong, F.,Kong, W.,Chang, J.H.,Sun, J.D.,Zavorotinskaya, T.,Ye, Q.,Al-Sayah, M.A.,Jackson, E.,Junttila, M.R.,Fantin, V.R.,Ndubaku, C.O.,Sun, D.,Du, X.,Friedman, L.S.
Discovery of ORIC-533, an Orally Bioavailable CD73 Inhibitor That Maintains Activity in High AMP Environments to Reverse Tumor Immunosuppression.
J.Med.Chem., 68:22145-22169, 2025
Cited by
PubMed Abstract: Immunosuppressive adenosine (ADO) is catabolized from adenosine monophosphate (AMP) by CD73 in the tumor microenvironment and corresponds to poor patient prognosis in many cancers. Reducing levels of ADO via inhibition of CD73 may reverse this immunosuppression. Herein we describe the discovery of ORIC-533 (), an inhibitor of CD73 with subnanomolar biochemical potency and potent cellular activity in both human and mouse tumor cell lines. Compound rescues T-cell activation and cytokine production at low nanomolar concentrations, showing robust immunomodulatory activity. Notably, in high AMP environments compound also promotes CD8 T-cell proliferation. Oral dosing of reduces the concentration of ADO in the tumor microenvironment with a concomitant increase in CD8 cells, resulting in tumor growth inhibition in a syngeneic mouse model of cancer. The strong potency and oral bioavailability support a potential best-in-class profile for , a CD73 inhibitor that entered phase 1b in patients with multiple myeloma.
PubMed: 41139398
DOI: 10.1021/acs.jmedchem.5c02153
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.43 Å)
構造検証レポート
Validation report summary of 9r0g
検証レポート(詳細版)ダウンロードをダウンロード

252816

件を2026-04-29に公開中

PDB statisticsPDBj update infoContact PDBjnumon